In conclusion, in this report, we reveal that among patients with metastatic NSCLC treated with first-line PD-1 inhibition, a PD-L1 TPS greater than or equal to 90% is associated with a clinically meaningful survival benefit at three years of follow-up and more favorable immunologic profiles. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.